Cliff Holloway is to join Scancell Holdings Plc as chief executive on 10 January 2018, succeeding Richard Goodfellow who will remain on the company’s board of directors. Dr Holloway joins Scancell from the Australian genetic medicines company Benitec Biopharma Ltd where he was chief business and operations officer. As Scancell CEO, he will oversee the commercialisation of the UK company’s cancer vaccine portfolio. Dr Holloway has also been CEO at Immune System Therapeutics Ltd and Biosceptre International Ltd, both Australian companies. He holds a bachelor’s degree in pharmacy and a PhD in medicinal chemistry from the University of Nottingham, UK.
Scancell announced the appointment on 10 October 2017.
Copyright 2017 Evernow Publishing Ltd